Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies

Journal of Psychiatric Research

Volumn 68, Issue , 2015, Pages 316-328

  Réus, Gislaine Z ^a,b   Jansen, Karen ^a,c   Titus, Stephanie ^a   Carvalho, André F ^d   Gabbay, Vilma ^e   Quevedo, João ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Indoleamine 2,3 dioxygenase; Inflammation; Kynurenine pathway; Tryptophan

Indexed keywords

ANTIDEPRESSANT AGENT; CELECOXIB; CITALOPRAM; IMIPRAMINE; KYNURENINE; MINOCYCLINE; TRYPTOPHAN;

ADJUVANT THERAPY; ANTIDEPRESSANT ACTIVITY; COMORBIDITY; CYTOKINE PRODUCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOMATIZATION; TREATMENT RESISTANT DEPRESSION; ANIMAL; DEPRESSIVE DISORDER, MAJOR; METABOLISM; PHYSIOLOGY;

ANIMALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS;

EID: 84937973148     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.05.007     Document Type: Review

References (133)

1. Abdallah C.G., Averill L.A., Krystal J.H. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 2015, 1344(1):66-77.
2. Altmaier E., Emeny R.T., Krumsiek J., Lacruz M.E., Lukaschek K., Häfner S., et al. Metabolomic profiles in individuals with negative affectivity and social inhibition: a population-based study ofType D personality. Psychoneuroendocrinology 2013, 38:1299-1309.
3. Anderson G., Maes M., Berk M. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol 2012, 88:27-48.
4. Anderson G., Kubera M., Duda W., Lasoń W., Berk M., Maes M. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep 2013, 65:1647-1654.
5. Ara I., Bano S. Citalopram decreases tryptophan 2,3-dioxygenase activity and brain 5-HT turnover in swim stressed rats. Pharmacol Rep 2012, 64:558-566.
6. Baranyi A., Meinitzer A., Stepan A., Putz-Bankuti C., Breitenecker R.J., Stauber R., et al. Abiopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom 2013, 82:332-340.
7. Bay-Richter C., Linderholm K.R., Lim C.K., Samuelsson M., Träskman-Bendz L., Guillemin G.J., et al. Arole for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun 2015, 43:110-117.
8. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007, 52:46-54.
9. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
10. Bobo W.V., Shelton R.C. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Rev Neurother 2010, 10:651-670.
11. Browne C.A., O'Brien F.E., Connor T.J., Dinan T.G., Cryan J.F. Differential lipopolysaccharide-induced immune alterations in the hippocampus of two mouse strains: effects of stress. Neuroscience 2012, 225:237-248.
12. Busse M., Busse S., Myint A.M., Gos T., Dobrowolny H., Müller U.J., et al. Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses?. Eur Arch Psychiatry Clin Neurosci 2015, 265(4):321-329.
13. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetinetreatment. Biol Psychiatry 2003, 54:906-914.
14. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Biologicresponse- modifier-induced indoleamine 2, 3-dioxygenase activity in human peripheral blood mononuclear cell cultures. JImmunol 1987, 139:2414-2418.
15. Chen H.B., Li F., Wu S., An S.C. Hippocampus quinolinic acid modulates glutamate and NMDAR/mGluR1 in chronic unpredictable mild stress-induced depression. Sheng Li Xue Bao 2013, 65:577-585.
16. Chiarugi A., Calvani M., Meli E., Traggiai E., Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. JNeuroimmunol 2001, 120:190-198.
17. Claes S., Myint A.M., Domschke K., Del-Favero J., Entrich K., Engelborghs S., et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res 2011, 188:355-360.
18. Connolly K.R., Thase M.E. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011, 71:43-64.
19. Conwell Y., Heisel M.J. The elderly. The american psychiatric publishing textbook of suicide assessment and management 2012, 367-388. American Psychiatric Publishing, Arlington, VA. 2nd ed. R.I. Simon, R.E. Hales (Eds.).
20. Corona A.W.1, Huang Y., O'Connor J.C., Dantzer R., Kelley K.W., Popovich P.G., et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. JNeuroinflammation 2010, 7:93.
21. Corona A.W., Norden D.M., Skendelas J.P., Huang Y., O'Connor J.C., Lawson M., et al. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activationand depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav Immun 2013, 31:134-142.
22. Crown W.H., Finkelstein S., Berndt E.R., Ling D., Poret A.W., Rush A.J., et al. The impact of treatment-resistant depression on health care utilization and costs. JClin Psychiatry 2002, 63:963-971.
23. Cutler J.A.1, Rush A.J., McMahon F.J., Laje G. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. JPsychopharmacol 2012, 26:360-367.
24. Dairam A., Antunes E.M., Saravanan K.S., Daya S. Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activityand alter brain neurotransmitter levels. Life Sci 2006, 79:2269-2274.
25. Davey K.J., O'Mahony S.M., Schellekens H., O'Sullivan O., Bienenstock J., Cotter P.D., et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacol Berl 2012, 221:155-169.
26. DeBattista C. Chapter 30: antidepressant agents. Basic & clinical pharmacology 2012, 521-542. McGraw-Hill. 12th ed. B.G. Katusung, S. Masters, A. Trevor (Eds.).
27. Delgado P.L. Depression: the case for a monoamine deficiency. JClin Psychiatry 2006, 61:7-11.
28. Dinel A.L., André C., Aubert A., Ferreira G., Layé S., Castanon N. Lipopolysaccharide-induced brain activation of the indoleamine 2,3-dioxygenase and depressive-like behaviorare impaired in a mouse model of metabolic syndrome. Psychoneuroendocrinology 2014, 40:48-59.
29. Dobos N.1, de Vries E.F., Kema I.P., Patas K., Prins M., Nijholt I.M., et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. JAlzheimers Dis 2012, 28:905-915.
30. Elgarf A.S., Aboul-Fotouh S., Abd-Alkhalek H.A., El Tabbal M., Hassan A.N., Kassim S.K., et al. Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model ofdepression in rats: reversibility by imipramine and pentoxifylline. Pharmacol Biochem Behav 2014, 126:152-162.
31. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
32. Elovainio M., Hurme M., Jokela M., Pulkki-Råback L., Kivimäki M., Hintsanen M., et al. Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressivesymptoms and carotid atherosclerosis: evidence from the Young Finns study. JAffect Disord 2011, 133:611-614.
33. Elovainio M., Hurme M., Jokela M., Pulkki-Råback L., Kivimäki M., Hintsanen M., et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study. Psychosom Med 2012, 74:675-681.
34. Erhardt S., Lim C.K., Linderholm K.R., Janelidze S., Lindqvist D., Samuelsson M., et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013, 38:743-752.
35. Ferrari A.J., Charlson F.J., Norman R.E., Patten S.B., Freedman G., Murray C.J., et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013, 10:e1001547.
36. Fitzgerald P., Cassidy Eugene M., Clarke G., Scully P., Barry S., Quigley Eamonn M.M., et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity ofsymptoms and psychiatric co-morbidity. Neurogastroenterol Motil 2008, 20:1291-1297.
37. Forrest C.M., Khalil O.S., Pisar M., Darlington L.G., Stone T.W. Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res 2013, 1504:1-15.
38. Forrest C.M., Khalil O.S., Pisar M., McNair K., Kornisiuk E., Snitcofsky M., et al. Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 2013, 254:241-259.
39. Franklin M., Bermudez I., Murck H., Singewald N., Gaburro S. Sub-chronic dietary tryptophan depletion an animal model of depression with improved face and good constructvalidity. JPsychiatr Res 2012, 46:239-247.
40. Fu X., Zunich S.M., O'Connor J.C., Kavelaars A., Dantzer R., Kelley K.W. Central administration of lipopolysaccharide induces depressive-like behavior invivo and activates brainindoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. JNeuroinflammation 2010, 7:43.
41. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. JChild Psychol Psychiatry 2010, 51:935-943.
42. Gabbay V., Liebes L., Katz Y., Liu S., Mendoza S., Babb J.S., et al. The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:37-44.
43. Gabbay V., Ely B.A., Babb J., Liebes L. The possible role of the kynurenine pathway in anhedonia in adolescents. JNeural Transm 2012, 119:253-260.
44. Gabbay V., Johnson A.R., Alonso C.M., Evans L.K., Babb J.S., Klein R.G. Anhedonia, but not Irritability, Is Associated with Illness Severity Outcomes in Adolescent Major Depression. J Child Adolesc Psychopharmacol. 2015, 25(3):194-200.
45. Galvão-de Almeida A., Quarantini L.C., Sampaio A.S., Lyra A.C., Parise C.L., Paraná R., et al. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression inhepatitis C. Brain Behav Immun 2011, 25:1491-1497.
46. Gibney S.M., McGuinness B., Prendergast C., Harkin A., Connor T.J. Poly I: C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours,kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 2013, 28:170-181.
47. Gibney S.M., Fagan E.M., Waldron A.M., O'Byrne J., Connor T.J., Harkin A. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int J Neuropsychopharmacol 2014, 17:917-928.
48. Godbout J.P., Moreau M., Lestage J., Chen J., Sparkman N.L., O'Connor J., et al. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immunesystem. Neuropsychopharmacology 2008, 33:2341-2351.
49. Grant R.S., Naif H., Espinosa M., Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 2000, 5:101-104.
50. Greenberg P.E., Fournier A.A., Sisitsky T., Pike C.T., Kessler R.C. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015 Feb, 76(2):155-162.
51. Guillemin G.J., Kerr S.J., Smythe G.A., Smith D.G., Kapoor V., Armati P.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. JNeurochem 2001, 78:842-853.
52. Henry C.J., Huang Y., Wynne A.M., Godbout J.P. Peripheral lipopolysaccharide (lps) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 2009, 23:309-317.
53. Heyes M.P., Lackner A. Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. JNeurochem 1990, 55:338-341.
54. Heyes M.P., Saito K., Major E.O., Milstien S., Markey S.P., Vickers J.H. Amechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116:1425-1450.
55. Hochstrasser T., Ullrich C., Sperner-Unterweger B., Humpel C. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience 2011, 184:128-138.
56. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 2012, 26:979-987.
57. Ignácio Z.M., Réus G.Z., Abelaira H.M., Quevedo J. Epigenetic and epistatic interactions between serotonin transporter and brain-derived neurotrophic factor genetic polymorphism: insights in depression. Neuroscience 2014, 275:455-468.
58. 1H NMR and UPLC-Q-TOF/MS for a comprehensive urinary metabonomics study on a rat model ofdepression induced by chronic unpredictable mild stress. PLoS One 2013, 8:e63624.
59. Kegel M.E., Bhat M., Skogh E., Samuelsson M., Lundberg K., Dahl M.L., et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res 2014, 7:15-22.
60. Kelley K.W., O'Connor J.C., Lawson M.A., Dantzer R., Rodriguez-Zas S.L., McCusker R.H. Aging leads to prolonged duration of inflammation-induced depression-like behavior caused by BacillusCalmette-Guérin. Brain Behav Immun 2013, 32:63-69.
61. Kim J.P., Choi D.W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 1987, 23:423-432.
62. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. JClin Invest 2012, 122:2940-2954.
63. Kocki T., Wnuk S., Kloc R., Kocki J., Owe-Larsson B., Urbanska E.M. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. JNeural Transm 2012, 119:235-243.
64. Krause D.L., Riedel M., Müller N., Weidinger E., Schwarz M.J., Myint A.M. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated invitro blood culture from depressed patients. Inflammopharmacology 2012, 20:169-176.
65. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 132-136.
66. Lardy H.A. The role of tryptophan metabolites in regulating gluconeogenesis. Am J Clin Nutr 1971, 24:764-765.
67. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210:84-91.
68. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-likebehaviours in mice: focus on individual differences. Pharmacol Biochem Behav 2011, 98:161-168.
69. Lawson M.A., Kelley K.W., Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenaseexpression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 2011, 25:1569-1575.
70. Lawson M.A., Parrott J.M., McCusker R.H., Dantzer R., Kelley K.W., O'Connor J.C. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependentdepression-like behaviors. JNeuroinflammation 2013, 10:87.
71. Leklem J.E. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr 1971, 24:659-672.
72. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012, 38:426-432.
73. Lopresti A.L., Maker G.L., Hood S.D., Drummond P.D. Areview of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:102-111.
74. Mackay G.M., Forrest C.M., Christofides J., Bridel M.A., Mitchell S., Cowlard R., et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol 2009, 36:425-435.
75. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway,indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011, 32:264-273.
76. Mangoni A. The ''kynurenine shunt'' and depression. Adv Biochem Psychopharmacol 1974, 11:293-298.
77. Martinez P., Tsai A.C., Muzoora C., Kembabazi A., Weiser S.D., Huang Y., et al. Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. JAcquir Immune Defic Syndr 2014, 65:456-462.
78. Mayhew J., Beart P.M., Walker F.R. Astrocyte and microglial control of glutamatergic signaling: a primer on understanding the disruptive role of chronic stress. JNeuroendocrinol 2015, (in press). 10.1111/jne.12273.
79. McInnis O.A., Matheson K., Anisman H. Living with the unexplained: coping, distress, and depression among women with chronic fatigue syndrome and/or fibromyalgia compared to an autoimmune disorder. Anxiety Stress Coping 2014, 27:601-618.
80. Mellor A.L., Munn D.H. Tryptophan catabolism and t-cell tolerance: immunosuppression by starvation?. Immunol Today 1999, 20:469-473.
81. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 111:135-370.
82. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulated cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006, 107:25-37.
83. Molteni R., Macchi F., Zecchillo C., Dell'agli M., Colombo E., Calabrese F., et al. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol 2013, 23:1645-1655.
84. Moreau M., Lestage J., Verrier D., Mormede C., Kelley K.W., Dantzer R., et al. Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. JInfect Dis 2005, 192(3):537-544.
85. Moreau M., André C., O'Connor J.C., Dumich S.A., Woods J.A., Kelley K.W., et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed bychronic depressive-like behavior. Brain Behav Immun 2008, 22:1087-1095.
86. Myint A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012, 270:1375-1385.
87. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. The role of the kynurenine metabolism in major depression: evidence of impaired neuroprotection. JAffect Disord 2007, 98:143-151.
88. Myint A.M., Schwarz M.J., Muller N. The role of the kynurenine metabolism in major depression. JNeural Transm 2012, 119:245-251.
89. Myint A.M., Bondy B., Baghai T.C., Eser D., Nothdurfter C., Schüle C., et al. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene. Brain Behav Immun 2013, 31:128-133.
90. Norden D.M., Devine R., Bicer S., Jing R., Reiser P.J., Wold L.E., et al. Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue. Physiol Behav 2015, (in press).
91. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. JPsychiatr Res 2007, 41:326-331.
92. O'Connor J.C., André C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. JNeurosci 2009, 29:4200-4209.
93. O'Connor J.C., Lawson M.A., André C., Briley E.M., Szegedi S.S., Lestage J., et al. Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. JImmunol 2009, 182:3202-3212.
94. O'Connor J.C., Lawson M.A., André C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
95. Ogawa S., Fujii T., Koga N., Hori H., Teraishi T., Hattori K., et al. Plasma L-tryptophan concentration in major depressive disorder: new data and meta-analysis. JClin Psychiatry 2014, 75:e906-e915.
96. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. JNeurochem 1998, 70:299-307.
97. O'Leary O.F., Dinan T.G., Cryan F.J. Faster, better, stronger: towards new antidepressant therapeautic strategies. Eur J Pharmacol 2014, Epub ahead of print. 10.1016/j.ejphar.2014.07.046.
98. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982, 247:184-187.
99. Pertl M.M., Hevey D., Boyle N.T., Hughes M.M., Collier S., O'Dwyer A.M., et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun 2013, 34:108-119.
100. Pertz H., Back W. Synthesis and resolution of chiral ring opened serotonin analogs of the 5-hydroxykynuramine type. Pharm Acta Helv 1988, 63:128-131.
101. Qiu H.M., Yang J.X., Jiang X.H., Fei H.Z., Liu D., Hu X.Y., et al. Upregulating serotonin transporter expression and downregulating monoamine oxidase-A and indoleamine 2, 3-dioxygenase expression involved in the antidepressant effect of sodium valproate in a rat model. Neuroreport 2014, 25:1338-1343.
102. Quagliariello E., Papa S., Saccone C., Alifano A. Effect of 3-hydroxyanthranilic acid on the mitochondrial respiratory system. Biochem J 1964, 91:137-146.
103. Quak J., Doornbos B., Roest A.M., Duivis H.E., Vogelzangs N., Nolen W.A., et al. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatoryimmune activity and depressive symptoms?. Psychoneuroendocrinology 2014, 45:202-210.
104. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2009, 15:393-403.
105. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
106. Reeves W.C., Strine T.W., Pratt L.A., Thompson W., Ahluwalia I., Dhingra S.S., et al. Centers for Disease Control and Prevention (CDC). Mental illness surveillance among adults in the United States. MMWR Surveill Summ 2011, 60(Suppl.3):1-29.
107. Réus G.Z., Dos Santos M.A., Abelaira H.M., Ribeiro K.F., Petronilho F., Vuolo F., et al. Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behav Brain Res 2013, 242:40-46.
108. Réus G.Z., Vieira F.G., Abelaira H.M., Michels M., Tomaz D.B., dos Santos M.A., et al. MAPK signaling correlates with the antidepressant effects of ketamine. JPsychiatr Res 2014, 55:15-21.
109. Réus G.Z., Carlessi A.S., Titus S.E., Abelaira H.M., Ignácio Z.M., da Luz J.R., et al. Asingle dose of s-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation. Dev Neurobiol 2015, (in press).
110. Réus G.Z., Nacif M.P., Abelaira H.M., Tomaz D.B., dos Santos M.A., Carlessi A.S., et al. Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci Lett 2015, 584:83-87.
111. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripherallipopolysaccharide immune challenge. Horm Behav 2012, 62:202-209.
112. Savitz J., Dantzer R., Wurfel B.E., Victor T.A., Ford B.N., Bodurka J., et al. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology 2015, 52:200-211.
113. Savitz J., Drevets W.C., Wurfel B.E., Ford B.N., Bellgowan P.S., Victor T.A., et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun 2015, S0889-1591(15)00026-4.
114. Savitz J., Drevets W.C., Smith C.M., Victor T.A., Wurfel B.E., Bellgowan P.S., et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015, 40:463-471.
115. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. JNeuropsychiatry Clin Neurosci 1965, 7:524-533.
116. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
117. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001, 50:521-530.
118. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. JPsychiatr Res 2008, 42:151-157.
119. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., et al. Severe depression is associated with increased quinolinic acid immunoreactivity in the dorsal and ventral anterior cingulum: further evidence for an immune modulation of glutamatergic neurotransmission?. JNeuroinflammation 2011, 8:94.
120. Stone T.W., Behan W.M., MacDonald M., Darlington L.G. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids 2000, 19:275-281.
121. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011, 25:1272-1278.
122. Swardfager W., Herrmann N., Dowlati Y., Oh P.I., Kiss A., Walker S.E., et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology 2009, 34:1560-1566.
123. Takikawa O. Biochemical and medical aspects of the indoeamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem Biophys Res Commun 2005, 338:12-19.
124. Trivedi M.H., Hollander E., Nutt D., Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. JClin Psychiatry 2008, 69:246-258.
125. van Praag H.M., Korf J. Apilot study of some kinetic aspects of the metabolism of 5-hydroxytrptamine in depressive patients. Biol Psychiatry 1971, 3:105-112.
126. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
127. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10:538-544.
128. Willner P., Sampson D., Phillips G., Muscat R. Amatching law analysis of the effects of dopamine receptor antagonists. Psychopharmacol Berl 1990, 101:560-567.
129. Xie W., Cai L., Yu Y., Gao L., Xiao L., He Q., et al. Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior inrats with chronic temporal lobe epilepsy. JNeuroinflammation 2014, 11:41.
130. Yang J.M., Rui B.B., Chen C., Chen H., Xu T.J., Xu W.P., et al. Acetylsalicylic acid enhances the anti-inflammatory effect of fluoxetine through inhibition of NF-κB, p38-MAPK and ERK1/2 activation in lipopolysaccharide-induced BV-2 microglia cells. Neuroscience 2014, 275:296-304.
131. Zhu H., Bogdanov M.B., Boyle S.H., Matson W., Sharma S., Matson S., et al. Pharmacometabolomics Research Network. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 2013, 8:e68283.
132. Zhu X., Jing L., Chen C., Shao M., Fan Q., Diao J., et al. Danzhi Xiaoyao San ameliorates depressive-like behavior by shifting toward serotonin via the downregulation of hippocampal indoleamine 2,3-dioxygenase. JEthnopharmacol 2015, 160:86-93.
133. Zoga M., Oulis P., Chatzipanagiotou S., Masdrakis V.G., Pliatsika P., Boufidou F., et al. Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females. InVivo 2014, 28:633-638.